Global Nebulizers Market is projected to grow at a CAGR of 11.06% between 2025 to 2030.
A nebulizer is a device that changes the medication from a liquid into the mist form which can be easily inhaled into the lungs. When inhaled, the medication reaches even the smaller airways and works more effectively. The devices are the preferred choice when delivering medications to infants, small children, or patient who has difficulty using inhalers. Nebulization is used for both – immediate relief as well as maintenance therapy for various respiratory disorders.
The market is expected to show robust growth during the given forecast period. The growth in the market may be attributed to the rising prevalence of respiratory diseases across the globe. WHO reports a prevalence of 251 million cases of COPD globally in 2016 with 3.17 million deaths due to COPD in 2015. Rising adoption and preference of homecare products for the treatment and management of respiratory diseases will further augment the market for nebulizers. However, wastage of the medication during the drug delivery using a nebulizer might restrict the growth of the market during the given time frame.
The increasing rate of respiratory problems.
Asthma has become one of the major concerns, affecting both adults and children, globally. According to the data given by the World Health Organization, asthma had affected around 262 million people in the year 2019 and had caused around 461,000 deaths. Other respiratory problems, such as chronic obstructive pulmonary diseases have also become a major cause of concern, worldwide. The WHO had stated that COPD is the third leading cause of death, globally, and had caused an estimated number of 3.23 million deaths, in the year 2019. More than 80% of the deaths had occurred in low and middle-income nations. Major companies have been introducing novel and advanced nebulizers for their customers, in the past few years. For instance, Philips, one of the key players in the market, provides the InnoSpire Essence Compressor nebulizer system to their customers. The product provides efficient and fast drug delivery in a compressor nebulizer system. These trends are expected to play a major role, in the overall market growth, during the forecast period.
Latest Developments.
Many companies are investing a significant sum of capital to develop novel and advanced solutions for their customers.
In June 2021, Glenmark Pharma, a major drug developer, announced that it had received approval from the United States health regulator for Arformoterol Tartrate Inhalation Solution, which has been used to treat conditions and problems like emphysema and chronic bronchitis in the United States market. The company had stated that their novel product would be manufactured in the company's North American production facility in North Carolina. This has become the firm's first nebulizer approval.
In December 2020, AireHealth, an advanced and innovative digital health firm enhancing healthy living through affordable treatments, announced that it had received a novel and major 510K clearance from the United States Food and Drug Administration for its flagship and advanced connected nebulizer. The firm had stated that the device had been an electronic vibrating mesh and portable nebulizer, which had been designed to nebulize liquid medications for inhalation. The firm had also stated that the nebulizer would be sold and marketed under a brand name, VitalMed. This development is expected to enhance the company's share in the market, in the coming years.
Impact of COVID-19.
COVID-19 pandemic had a positive impact on the market, because of the rise in the number of people having respiratory and other related problems. There had also been a reported shortage of oxygen in various nations, which has also alleviated the demand for nebulizers in the market. For instance, in June 2020, an academic research paper regarding the patients inhaling hydrogen-oxygen mixed gas, during the COVID-19, was produced by Asclepius Meditec's Hydrogen Oxygen Generator with Nebulizer, had been published in the reputed Journal of Thoracic Disease. The research stated that the hydrogen-oxygen mixed gas inhalation could enhance diseases dyspnea and severity in patients with COVID problems. There had been other developments in the market, during the pandemic. In October 2020, the National Institute of Pharmaceutical Education and Research in Hyderabad had been working with the regulatory authorities in India, intending to get approval for its novel nebulizer-based inhalation therapy for its use in COVID patients. Moreover, countries like India, in April 2021, had allowed the import of 17 medical devices, that included oxygen canisters, nebulizers, and others, with mandatory declarations immediately after the product's custom clearance and before its overall sales in the market. This development had been expected to have a positive impact on the market.
Segmentation: